Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
9257 | 1173 | 32.1 | 60% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
171 | 3 | MONASCUS//CITRININ//MONASCUS PURPUREUS | 58457 |
419 | 2 | STATINS//EZETIMIBE//SIMVASTATIN | 16502 |
9257 | 1 | PRAVASTATIN//HMG COA REDUCTASE INHIBITORS//MEVALONIC ACID | 1173 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | PRAVASTATIN | authKW | 182629 | 6% | 10% | 73 |
2 | HMG COA REDUCTASE INHIBITORS | authKW | 119610 | 6% | 7% | 69 |
3 | MEVALONIC ACID | authKW | 99937 | 2% | 20% | 19 |
4 | SIMVASTATIN | authKW | 75588 | 7% | 4% | 78 |
5 | LOVASTATIN | authKW | 71820 | 4% | 6% | 48 |
6 | CAS 81131 70 6 | authKW | 58567 | 0% | 75% | 3 |
7 | ANDRX S INC | address | 52060 | 0% | 100% | 2 |
8 | LOVASTATIN SIMVASTATIN | authKW | 52060 | 0% | 100% | 2 |
9 | MEVALOTIN R | authKW | 52060 | 0% | 100% | 2 |
10 | SIMVASTATINE | authKW | 52060 | 0% | 100% | 2 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 3373 | 32% | 0% | 380 |
2 | Cardiac & Cardiovascular System | 3153 | 21% | 0% | 248 |
3 | Peripheral Vascular Diseases | 1704 | 12% | 0% | 138 |
4 | Medicine, General & Internal | 1515 | 18% | 0% | 208 |
5 | Medicine, Research & Experimental | 365 | 8% | 0% | 90 |
6 | Endocrinology & Metabolism | 257 | 7% | 0% | 81 |
7 | Toxicology | 136 | 4% | 0% | 47 |
8 | Biochemistry & Molecular Biology | 46 | 10% | 0% | 119 |
9 | Chemistry, Medicinal | 37 | 2% | 0% | 29 |
10 | Nutrition & Dietetics | 33 | 2% | 0% | 24 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ANDRX S INC | 52060 | 0% | 100% | 2 |
2 | OTC PROD | 34706 | 0% | 67% | 2 |
3 | ANALYT METAB S SHINJUKU KU | 26030 | 0% | 100% | 1 |
4 | ANIM SCI TOXICOL S SHINJUKU KU | 26030 | 0% | 100% | 1 |
5 | BDR AMP CECOS | 26030 | 0% | 100% | 1 |
6 | BIOL PRINCIPLES SPORT | 26030 | 0% | 100% | 1 |
7 | BIOL S SHINJUKU KU | 26030 | 0% | 100% | 1 |
8 | BIOSTAT DISCOVERY EARLY DEV PROJECTS | 26030 | 0% | 100% | 1 |
9 | BIOSTAT INT | 26030 | 0% | 100% | 1 |
10 | BOLU IZZET MED | 26030 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ATHEROSCLEROSIS | 11958 | 6% | 1% | 70 |
2 | CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 11451 | 4% | 1% | 46 |
3 | ARTERY | 3961 | 1% | 2% | 9 |
4 | AMERICAN JOURNAL OF CARDIOLOGY | 3936 | 5% | 0% | 64 |
5 | JOURNAL OF LIPID RESEARCH | 2528 | 2% | 0% | 29 |
6 | JOURNAL OF CLINICAL PHARMACOLOGY | 1885 | 2% | 0% | 20 |
7 | METABOLISM-CLINICAL AND EXPERIMENTAL | 1657 | 2% | 0% | 24 |
8 | DRUGS | 1645 | 2% | 0% | 19 |
9 | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1590 | 2% | 0% | 21 |
10 | DRUG INVESTIGATION | 1423 | 0% | 1% | 4 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PRAVASTATIN | 182629 | 6% | 10% | 73 | Search PRAVASTATIN | Search PRAVASTATIN |
2 | HMG COA REDUCTASE INHIBITORS | 119610 | 6% | 7% | 69 | Search HMG+COA+REDUCTASE+INHIBITORS | Search HMG+COA+REDUCTASE+INHIBITORS |
3 | MEVALONIC ACID | 99937 | 2% | 20% | 19 | Search MEVALONIC+ACID | Search MEVALONIC+ACID |
4 | SIMVASTATIN | 75588 | 7% | 4% | 78 | Search SIMVASTATIN | Search SIMVASTATIN |
5 | LOVASTATIN | 71820 | 4% | 6% | 48 | Search LOVASTATIN | Search LOVASTATIN |
6 | CAS 81131 70 6 | 58567 | 0% | 75% | 3 | Search CAS+81131+70+6 | Search CAS+81131+70+6 |
7 | LOVASTATIN SIMVASTATIN | 52060 | 0% | 100% | 2 | Search LOVASTATIN+SIMVASTATIN | Search LOVASTATIN+SIMVASTATIN |
8 | MEVALOTIN R | 52060 | 0% | 100% | 2 | Search MEVALOTIN+R | Search MEVALOTIN+R |
9 | SIMVASTATINE | 52060 | 0% | 100% | 2 | Search SIMVASTATINE | Search SIMVASTATINE |
10 | FLUVASTATIN | 41036 | 2% | 6% | 25 | Search FLUVASTATIN | Search FLUVASTATIN |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | PLOSKER, GL , WAGSTAFF, AJ , (1996) FLUVASTATIN - A REVIEW OF ITS PHARMACOLOGY AND USE IN THE MANAGEMENT OF HYPERCHOLESTEROLAEMIA.DRUGS. VOL. 51. ISSUE 3. P. 433-459 | 53 | 64% | 93 |
2 | PLOSKER, GL , MCTAVISH, D , (1995) SIMVASTATIN - A REAPPRAISAL OF ITS PHARMACOLOGY AND THERAPEUTIC EFFICACY IN HYPERCHOLESTEROLEMIA.DRUGS. VOL. 50. ISSUE 2. P. 334-363 | 74 | 47% | 67 |
3 | TODD, PA , GOA, KL , (1990) SIMVASTATIN - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN HYPERCHOLESTEROLEMIA.DRUGS. VOL. 40. ISSUE 4. P. 583-607 | 45 | 82% | 151 |
4 | DESAGER, JP , HORSMANS, Y , (1996) CLINICAL PHARMACOKINETICS OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS.CLINICAL PHARMACOKINETICS. VOL. 31. ISSUE 5. P. 348-371 | 61 | 46% | 140 |
5 | LENNERNAS, H , FAGER, G , (1997) PHARMACODYNAMICS AND PHARMACOKINETICS OF THE HMG-COA REDUCTASE INHIBITORS - SIMILARITIES AND DIFFERENCES.CLINICAL PHARMACOKINETICS. VOL. 32. ISSUE 5. P. 403 -425 | 42 | 48% | 348 |
6 | MCTAVISH, D , SORKIN, EM , (1991) PRAVASTATIN - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN HYPERCHOLESTEROLEMIA.DRUGS. VOL. 42. ISSUE 1. P. 65-89 | 36 | 86% | 95 |
7 | GARCIA, MJ , REINOSO, RF , NAVARRO, AS , PROUS, JR , (2003) CLINICAL PHARMACOKINETICS OF STATINS.METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY. VOL. 25. ISSUE 6. P. 457-481 | 40 | 51% | 60 |
8 | CORSINI, A , MAGGI, FM , CATAPANO, AL , (1995) PHARMACOLOGY OF COMPETITIVE INHIBITORS OF HMG-COA REDUCTASE.PHARMACOLOGICAL RESEARCH. VOL. 31. ISSUE 1. P. 9-27 | 61 | 37% | 186 |
9 | DESLYPERE, JP , (1995) THE ROLE OF HMG-COA REDUCTASE INHIBITORS IN THE TREATMENT OF HYPERLIPIDEMIA - A REVIEW OF FLUVASTATIN.CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL. VOL. 56. ISSUE 2. P. 111-128 | 39 | 70% | 27 |
10 | ENDO, A , (1992) THE DISCOVERY AND DEVELOPMENT OF HMG-COA REDUCTASE INHIBITORS.JOURNAL OF LIPID RESEARCH. VOL. 33. ISSUE 11. P. 1569-1582 | 33 | 57% | 478 |
Classes with closest relation at Level 1 |